Your Health, We Care
Release date: 2026-01-23 17:54:50 Recommended: 9
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor, primarily indicated for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Its indications cover the following two categories of patients:
First-line therapy: For ALK-positive metastatic NSCLC patients who have not received prior ALK inhibitor treatment. It prolongs survival by inhibiting tumor growth and metastasis.
Second-line and subsequent therapy: For ALK-positive NSCLC patients whose disease has progressed or who have developed resistance after treatment with other ALK inhibitors (e.g., crizotinib, alectinib, etc.). It can overcome certain drug-resistant mutations.
Patients with brain metastases: Lorlatinib can penetrate the blood-brain barrier and exerts significant efficacy in ALK-positive NSCLC patients complicated with brain metastases.
Patients with specific gene mutations: Applicable to tumors caused by ALK gene fusions (e.g., EML4-ALK) or other ALK-related variants, which must be confirmed by genetic testing.
Strictly follow medical advice: Lorlatinib is a prescription drug. Dosage should be adjusted based on the patient's genetic test results, medical history and tolerance. Do not administer the drug without medical supervision.
Side effect management: Common side effects include hypercholesterolemia, edema and peripheral neuropathy. Regular monitoring and proper management under medical guidance are required.
Contraindicated populations: Patients with hypersensitivity to any component of the drug or severe hepatic insufficiency should use this drug with caution.
If meeting the above-mentioned indications, it is recommended that an individualized treatment plan be formulated after evaluation by an oncologist. Regular re-examinations should be conducted during treatment to monitor efficacy and adverse reactions.
